Thursday, June 21, 2018
Another possible option for NRAS mutant melanoma patients
Sadly, today's post is in keeping with those of the past two days, in that this abstract doesn't give a great deal of definitive info. By way of explanation, here is a link to prior posts (with links within) that address treatment for folks with: NRAS-mutant melanoma
This ASCO 2017 report noted: NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts.
After which I wrote this: In this study, 224 NRAS mutated melanoma patients were studied. 180 were treated with ipi, 98 with anti-PD-1 and 1 was given the ipi/nivo combo. The overall response rate was 15% for those treated with ipi and 34% for those treated with anti-Pd-1....which is in keeping with response rates for those drugs generally.
Despite the fairly optimistic (For melanoma world, don't 'cha know???!!) report above, there are other studies (and more importantly ~ real live NRAS friends and peeps) who have struggled with attaining good responses on current therapies. The mice and researchers now share this:
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Echevarria-Vargas, Reyes-Uribe, Guterres, et al. EMBO Mol Med. 2018 Apr 12.
Perhaps this will help send therapy for NRAS-mutant melanoma in a better direction. Hang tough my dear NRAS ratties!!! - c